Weekly low-dose Semustine in a patient with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) coupled with subcutaneous involvement and positive O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation

详细信息    查看全文

• 作者：Wei Ren (1)
  Li Xie (1)
  Jing Yan (1)
  Weiwei Kong (1)
  Yang Yang (1)
  Lijing Zhu (1)
  Wenjing Hu (1)
  Xinyun Xu (2)
  Xiaoping Qian (1)
  Baorui Liu (1)
  
• 关键词：peripheral T ; cell lymphoma (PTCL) ; Semustine ; chemotherapy ; O6 ; methylguanine ; DNA methyltransferase promoter methylation (MGMT)
• 刊名：The Chinese-German Journal of Clinical Oncology
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：11
• 期：9
• 页码：544-547
• 全文大小：382KB
• 参考文献：1. Savage KJ. Peripheral T-cell lymphomas. Blood Rev, 2007, 21: 201鈥?16. CrossRef
  2. Vose J, Armitage J, Weisenburger D, / et al. International peripheral Tcell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol, 2008, 26: 4124鈥?130. CrossRef
  3. Agostinelli C, Piccaluga PP, Went P, / et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol, 2008, 61: 1160鈥?167. CrossRef
  4. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol, 2011, 8: 587鈥?96. CrossRef
  5. Sabattini E, Bacci F, Sagramoso C, / et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica, 2010, 102: 83鈥?7.
  6. Savage KJ, Ferreri AJ, Zinzani PL, / et al. Peripheral T-cell lymphoma-not otherwise specified. Crit Rev Oncol Hematol, 2011, 79: 321鈥?29. CrossRef
  7. Zucali PA, Giovannetti E, Destro A, / et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res, 2011, 17: 2581鈥?590. CrossRef
  8. Righi L, Papotti MG, Ceppi P, / et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol, 2010, 28: 1534鈥?539. CrossRef
  9. Uramoto H, Onitsuka T, Shimokawa H, / et al. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Anticancer Res, 2010, 30: 4309鈥?315.
  10. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res, 2007, 67: 5831鈥?839. CrossRef
  11. Sequist LV, Bell DW, Lynch TJ, / et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol, 2007, 25: 587鈥?95. CrossRef
  12. Sequist LV, Martins RG, Spigel D, / et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol, 2008, 26: 2442鈥?449. CrossRef
  13. Hegi ME, Diserens AC, Gorlia T, / et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005, 352: 997鈥?003. CrossRef
  14. Fabi A, Metro G, Russillo M, et al. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. BMC Cancer, 2009, 9: 101. CrossRef
  15. Oh J, Bilbao JM, Tsao MN, / et al. Recurrent PNET with MGMT methylation responds to temozolomide. Can J Neurol Sci, 2009, 36: 654鈥?57.
  16. Rovin RA, Winn R. Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. J Neurosurg Spine, 2007, 6: 447鈥?50. CrossRef
  17. McCormack AI, McDonald KL, Gill AJ, / et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf), 2009, 71: 226鈥?33. CrossRef
  18. Tanaka H, Sasayama T, Nishihara M, / et al. Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. Neurol Med Chir (Tokyo), 2010, 50: 689鈥?93. CrossRef
  19. Zhang Q, Jiang ZP, Jin XQ. Clinical characteristics for 112 cases with non-Hodgkin鈥檚 lymphoma. Chinese-German J Clin Oncol, 2008, 7: 546鈥?48. CrossRef
  20. Eisenhauer EA, Therasse P, Bogaerts J, / et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45: 228鈥?47. CrossRef
  
• 作者单位：Wei Ren (1)
  Li Xie (1)
  Jing Yan (1)
  Weiwei Kong (1)
  Yang Yang (1)
  Lijing Zhu (1)
  Wenjing Hu (1)
  Xinyun Xu (2)
  Xiaoping Qian (1)
  Baorui Liu (1)
  
  1. Comprehensive Cancer Center of Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Nanjing, 210008, China
  2. Department of Pathology, Drum Tower Hospital, Nanjing, 210008, China
  

文摘

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with no treatment consensus and poor prognosis. We herein described an extraordinary refractory case of PTCL-NOS with widely involvement of subcutaneous tissue, which showed an excellent response to Semustine personalized chemotherapy based on the detection finding of positive O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. This is the first english report to indicate that single nitrosourea agent such as Semustine may have good efficacy and safety for widespread subcutaneous involvement of PTCL-NOS with positive MGMT promoter methylation.